ALGS

Aligos Therapeutics, Inc. [ALGS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALGS Stock Summary

Top ALGS Correlated Resources

ALGS


Top 10 Correlated Stocks

ALGS


In the News

09:05 04 Dec 2022 ALGS

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).

04:15 04 Dec 2022 ALGS

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.

07:30 04 Dec 2022 ALGS

Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute's 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA

Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023

04:05 04 Dec 2022 ALGS

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 pm ET at the Marriot Marquis in New York City.

04:05 04 Dec 2022 ALGS

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of U.S. financial markets.

04:05 04 Dec 2022 ALGS

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 after the close of U.S. financial markets.

01:49 04 Dec 2022 ALGS

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

09:00 04 Dec 2022 ALGS

Aligos Therapeutics Stock (ALGS): Why The Price Substantially Fell

The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) fell by 56.74% in the most recent trading session. This is why it happened.

06:21 04 Dec 2022 ALGS

Why Aligos Therapeutics Stock Crumbled Today

The company is pulling the plug on a once-promising treatment targeting hepatitis B.

04:05 04 Dec 2022 ALGS

Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 5:15 pm ET. Both the presentation and the Q&A session will be held virtually.

ALGS Financial details

Company Rating
Neutral
Market Cap
38.13M
Income
-111.87M
Revenue
10.74M
Book val./share
2.85
Cash/share
3.33
Dividend
-
Dividend %
-
Employees
89
Optionable
No
Shortable
Yes
Earnings
02 Nov 2022
P/E
-0.29
Forward P/E
-
PEG
0.04
P/S
3.82
P/B
0.34
P/C
0.28
P/FCF
-0.41
Quick Ratio
4.66
Current Ratio
4.91
Debt / Equity
0.08
LT Debt / Equity
0.08
-
-
EPS (TTM)
-2.64
EPS next Y
-
EPS next Q
-
EPS this Y
-70.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
11.18%
EPS Q/Q
-6.38%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
64.75%
Inst Trans
-5.31%
ROA
-68%
ROE
-75%
ROC
-0.85%
Gross Margin
38%
Oper. Margin
-1051%
Profit Margin
-1042%
Payout
-
Shs Outstand
39.72M
Shs Float
20.82M
-
-
-
-
Target Price
-
52W Range
0.86-13.78
52W High
-
52W Low
-
RSI
44
Rel Volume
0.51
Avg Volume
73.52K
Volume
37.56K
Perf Week
-10.58%
Perf Month
-10.58%
Perf Quarter
-30.08%
Perf Half Y
-27.91%
-
-
-
-
Beta
1.97083
-
-
Volatility
0.02%, 0.05%
Prev Close
-3.64%
Price
0.93
Change
-4.12%

ALGS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2020-12-31 2021-12-31
Revenue per share
00.44
Net income per share
-10.87-12.85
Operating cash flow per share
-7.44-11.58
Free cash flow per share
-7.64-11.67
Cash per share
24.3819.1
Book value per share
22.0318.49
Tangible book value per share
22.0318.49
Share holders equity per share
22.0318.49
Interest debt per share
2.361.45
Market cap
281.37M27.57M
Enterprise value
73.99M-144.79M
P/E ratio
-2.59-0.21
Price to sales ratio
06.32
POCF ratio
-3.79-0.24
PFCF ratio
-3.69-0.24
P/B Ratio
1.280.15
PTB ratio
1.280.15
EV to sales
0-33.22
Enterprise value over EBITDA
-0.781.16
EV to operating cash flow
-11.25
EV to free cash flow
-0.971.24
Earnings yield
-0.39-4.66
Free cash flow yield
-0.27-4.23
Debt to equity
0.050.06
Debt to assets
0.170.22
Net debt to EBITDA
2.191.39
Current ratio
8.265.25
Interest coverage
-9.280
Income quality
0.680.9
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
06.54
Research and developement to revenue
023.89
Intangibles to total assets
00
Capex to operating cash flow
0.030.01
Capex to revenue
0-0.2
Capex to depreciation
-0.62-0.24
Stock based compensation to revenue
03.09
Graham number
73.3973.12
ROIC
-0.42-0.65
Return on tangible assets
-0.41-0.55
Graham Net
19.8514.03
Working capital
219.74M165.47M
Tangible asset value
00
Net current asset value
204.75M153.79M
Invested capital
0.060.08
Average receivables
00
Average payables
3.31M3.16M
Average inventory
00
Days sales outstanding
00
Days payables outstanding
00
Days of inventory on hand
00
Receivables turnover
00
Payables turnover
00
Inventory turnover
00
ROE
-0.49-0.69
Capex per share
-0.21-0.09

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.040.010.060.090.1
Net income per share
-0.78-0.89-0.84-0.47-0.44
Operating cash flow per share
-0.6-0.89-0.48-0.59-0.4
Free cash flow per share
-0.6-0.89-0.49-0.59-0.4
Cash per share
5.714.54.313.733.33
Book value per share
5.124.363.63.212.85
Tangible book value per share
5.124.363.63.212.85
Share holders equity per share
5.124.363.63.212.85
Interest debt per share
0.290.340.340.320.32
Market cap
657.62M502.6M91.4M51.63M47.04M
Enterprise value
430.31M330.24M1.21M-6.11M-26.37M
P/E ratio
-4.96-3.33-0.64-0.65-0.63
Price to sales ratio
427.861.37K35.5513.9811.46
POCF ratio
-25.92-13.41-4.47-2.06-2.74
PFCF ratio
-25.82-13.29-4.36-2.03-2.74
P/B Ratio
3.032.720.60.380.39
PTB ratio
3.032.720.60.380.39
EV to sales
279.97899.830.47-1.65-6.42
Enterprise value over EBITDA
-13.43-8.98-0.040.331.46
EV to operating cash flow
-16.96-8.81-0.060.241.54
EV to free cash flow
-16.9-8.73-0.060.241.54
Earnings yield
-0.05-0.08-0.39-0.39-0.4
Free cash flow yield
-0.04-0.08-0.23-0.49-0.36
Debt to equity
0.040.060.070.080.08
Debt to assets
0.180.220.270.250.26
Net debt to EBITDA
7.14.692.613.074.07
Current ratio
7.155.254.725.34.91
Interest coverage
00-413.45-96.19-40.66
Income quality
0.770.990.571.260.92
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
4.2126.482.512.051.28
Research and developement to revenue
18.377.9212.324.474.33
Intangibles to total assets
00000
Capex to operating cash flow
00.010.030.010
Capex to revenue
-0.06-0.92-0.2-0.090
Capex to depreciation
-0.1-0.33-0.52-0.380
Stock based compensation to revenue
2.349.951.471.080.85
Graham number
9.499.358.235.815.29
ROIC
-0.14-0.19-0.21-0.14-0.14
Return on tangible assets
-0.13-0.16-0.17-0.11-0.11
Graham Net
4.633.312.962.672.34
Working capital
213.89M165.47M153.72M136.03M119.55M
Tangible asset value
00000
Net current asset value
202.61M153.79M137.49M122.14M108.04M
Invested capital
0.060.080.090.10.11
Average receivables
00000
Average payables
2.68M2.89M3.26M2.76M2.85M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.15-0.2-0.23-0.15-0.15
Capex per share
0-0.01-0.01-0.010

ALGS Frequently Asked Questions

What is Aligos Therapeutics, Inc. stock symbol ?

Aligos Therapeutics, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol ALGS

What is Aligos Therapeutics, Inc. stock quote today ?

Aligos Therapeutics, Inc. stock price is $0.93 today.

Is Aligos Therapeutics, Inc. stock public?

Yes, Aligos Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated Stocks
Similar Market Cap